RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) announced today that it has been
named as one of the 2012 TSX Venture Top 50 companies.


The 2012 TSX Venture 50 is an annual ranking of strong performing emerging
companies listed on the TSX Venture Exchange. The TSX Venture 50 includes the
top 10 companies in five major industry sectors that have been identified as
leaders in Canada's public venture market. BioSyent is ranked fifth in the list
of ten leading Technology and Life Sciences companies for the year. Companies
are selected based on four equally weighted criteria - return on investment,
trading activity, market capitalization growth, and analyst coverage. The
results were obtained from data to December 31, 2011.


"With more than 2,200 companies listed on the TSX Venture Exchange, it is an
honour to have BioSyent named as one of this year's TSX Venture Top 50
companies," said Rene Goehrum, President and CEO of BioSyent Inc. "Thanks to the
hard work of our team and the tangible growth in both our revenue and profit,
the investment community is recognizing the value in Biosyent." 


More information on the TSX Venture Top 50 is available at
http://www.tmxmoney.com/en/research/tsxventure50.html.


BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada. The
Company is focused on medications that occupy a niche in the market, that are
unique either due to complexity of manufacture or provide novel technological or
therapeutic advantages, or that are backed by strong partners holding
intellectual property rights that are defendable. This strategy allows the
Company to market these medications as brands owned by, or licensed to, it.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX. 


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.

Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024